Back to Edarbi Tablet

Edarbi Tablet Uses in Pakistan

Edarbi Tablet (Azilsartan Medoxomil) is a prescription antihypertensive medicine used in Pakistan. This guide covers all its approved uses, indications, and other important information you should know.

Compiled by the PakVita Editorial Team · AI-assisted drafting with editorial review · Sourced from DRAP, WHO, BNF · Last updated:

Uses

Quick Answer

Edarbi Tablet (Azilsartan Medoxomil) is used to treat hypertension (high blood pressure) and reduce cardiovascular risk in hypertensive patients. It belongs to the angiotensin II receptor blocker (ARB) class and is available on prescription in Pakistan. Always take it at the correct dose as directed by your doctor or pharmacist.

Primary Uses at a Glance

Hypertension (high blood pressure)

Edarbi Tablet (Azilsartan Medoxomil) is used for hypertension (high blood pressure). This is the primary approved indication for azilsartan medoxomil in Pakistan.

As prescribed by your doctor. Standard adult dose: as directed, typically once daily.

Cardiovascular risk reduction in hypertensive patients

Edarbi Tablet is used to reduce cardiovascular risk in patients with hypertension. Controlling blood pressure lowers the risk of heart attack and stroke.

As prescribed by your doctor.

Combination hypertension management with other antihypertensives

Edarbi Tablet can be used in combination with other antihypertensive medicines for patients whose blood pressure is not adequately controlled by a single agent.

As prescribed by your doctor — do not add or change medicines without medical advice.

Other Uses

  • Hypertension management in patients not responding adequately to other ARBs

Edarbi Tablet Uses (Fayde / Kis kaam aati hai)

Edarbi Tablet contains Azilsartan Medoxomil and belongs to the angiotensin II receptor blocker (ARB) group. Below are all the approved and common uses of Edarbi Tablet in Pakistan.

Primary Uses (Mukhya Istemal)

  • Hypertension (high blood pressure)
  • Cardiovascular risk reduction in hypertensive patients
  • Combination hypertension management with other antihypertensives

Who Should Take It (Kin logon ke liye)

  • Adults with diagnosed hypertension (high blood pressure)
  • Patients whose blood pressure is not adequately controlled by other ARBs
  • Patients who need potent, once-daily blood pressure control under medical supervision

When NOT to Use Edarbi Tablet (Kab nahi leni chahiye)

  • If you are allergic to azilsartan medoxomil or any ARB
  • During the second and third trimester of pregnancy
  • Concomitant use with aliskiren in patients with diabetes or kidney disease

Summary

Edarbi Tablet is prescribed for hypertension and cardiovascular risk reduction. Always consult a doctor before starting or stopping this medicine.

The information in this guide is for educational purposes only.

Frequently Asked Questions

For which conditions is Edarbi Tablet most effective?

Edarbi Tablet is most effective for hypertension (high blood pressure). It may be used alone or in combination with other antihypertensives. Always take it for the condition your doctor has prescribed it for.

Can Edarbi Tablet be taken without a doctor's prescription?

No. Edarbi Tablet is a prescription medicine. Do not take it without a doctor's advice.

How long does Edarbi Tablet take to show results?

Blood pressure lowering effects are typically seen within 2 weeks of starting treatment. Full blood pressure reduction may take up to 4 weeks. Follow your doctor's advice on how long to continue treatment.

Can Edarbi Tablet be taken long-term?

Long-term use of Edarbi Tablet is common for hypertension management. Your doctor will monitor blood pressure and kidney function regularly during treatment.

What should I do if Edarbi Tablet does not seem to work?

If you feel Edarbi Tablet is not adequately controlling your blood pressure, do not increase the dose on your own. Consult your doctor to review your treatment plan.

Brand alternatives, same-class options, and other medicines used for the same conditions as Edarbi Tablet.

Sources

  1. DRAP Registered Products Database Drug Regulatory Authority of Pakistan
  2. WHO Model List of Essential Medicines, 23rd ed. (2023) World Health Organization
  3. British National Formulary (BNF) BMJ Group & Pharmaceutical Press

Medical disclaimer

This page is for educational use only and does not replace professional medical advice. Always confirm diagnosis, dose, and interactions with a qualified doctor or pharmacist before starting or changing any medicine.